GSK is sourcing early-stage science across a wide range of technologies and disease areas, while placing more selective bets ...
As British pharma giant AstraZeneca looks abroad to build new factories, GSK is sticking close to home, where it plans to plug hundreds of millions of pounds into the United Kingdom over the next two ...
As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the British drug giant feels prepared for any challenges that U.S. drug import ...
Hosted on MSN
GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment
GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a positive ...
Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month, GSK ...
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities is only natural. But that redistribution of resources will mean job cuts ...
Nov 3 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results